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S1 Methods
S1.1 Computational sequence design and analysis
scRNA sequences were designed using the reaction pathway engineering tools within NUPACK (nupack.org).2, 3 Within
each target test tube in the design ensemble, all on-target complexes had a target concentration of 2.5 nM and all off-target
complexes (consisting of all complexes of up to 4 strands) had a target concentration of 0 nM. Target test tubes displaying
target structures for on-target complexes are shown for the forward system (X a Y) in Figure 2a and for the reverse system in
(Y a X) in Figure S1a. In these panels, nucleotides are shaded to depict sequence constraints imposed by mRNAs X (magenta
shading) and Y (green shading). For the forward mechanism, the design algorithm selected an scRNA binding site from within
the full-length mRNA X sequence. For the reverse mechanism, we used RNAhyb to experimentally identify an accessible
window of the full-length mRNA Y, from which the designer selected an scRNA binding site. For a given design, the sequences
were optimized by mutating the sequence set to reduce the multi-tube ensemble defect.3 Designs were performed using RNA
parameters for 37◦C in 1M Na+.4 Chemical modifications (20OMe-RNA) used to reduce RNase-mediated degradation and
Mg++ (in buffer D) used to facilitate Dicer processing were not accounted for in the physical model.
For the final sequence designs, equilibrium analysis of the target test tubes reveals the contributions of structural defects
(fraction of nucleotides in the incorrect base-pairing state within the ensemble of an on-target complex) and concentration
defects (fraction of nucleotides in the incorrect base-pairing state because there is a deficiency in the concentration of an on-
target complex) to the overall multi-tube ensemble defect. Residual defects are displayed in Figure 2b for the forward system
and in Figure S1b for the reverse system. In these panels, tubes depict the predicted concentration and target structure for each
on-target complex, with nucleotides shaded to indicate the probability of adopting the depicted base-pairing state at equilibrium
(nucleotides shaded dark red adopt the depicted state with probability close to 1 and contribute negligible structural defect;
nucleotides shaded dark blue adopt the depicted state with probability close to 0 and contribute maximal structural defect). Bar
graphs depict the residual defect for each on-target complex in each tube.
It is interesting to note that when analyzed in isolation, the short RNA input Xs for the forward mechanism is predicted
to be relatively unstructured (Figure S2a), while the short RNA input Ys for the reverse mechanism is predicted to be highly
structured (Figure S2b) even though RNAhyb experimental data established that this subsequence is relatively accessible in the
context of the full-length mRNA Y. The short RNA input was not included in the Reactants tube due to the unreliability of
predictions for this short subsequence in isolation from the full-length mRNA.
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Figure S1: scRNA sequence design and analysis for the reverse molecular logic Y a X. (a) Target test tubes depicting the target structure
and target concentration for each on-target complex, with nucleotides shaded to depict sequence constraints imposed by mRNA input Y
(green nucleotides) or mRNA silencing target X (magenta nucleotides). In each tube, off-targets include all complexes of up to 4 strands (not
depicted). (b) Analysis of design quality over the design ensemble. Tubes depict the predicted concentration and target structure for each on-
target complex, with nucleotides shaded to indicate the probability of adopting the depicted base-pairing state at equilibrium. In the Reactants
tube, the scRNA reactant A·B is predicted to be well-formed with an accessible toehold ‘a*’. In the Intermediate tube, the internal toehold
‘c’ is predicted to nucleate with complement ‘c*’ with high probability, and there is some unwanted secondary structure in the hairpin loop.
In the Products tube, the waste duplex YS·A and the shRNA Dicer substrate B are both predicted to be well-formed (again with unwanted
secondary structure in the loop of B). On-target complexes that form at concentrations below the 2.5 nM target concentration indicate the
formation of off-target complexes at non-negligible concentrations. Bar graphs depict the residual defect for each on-target complex in each
tube. For all three tubes, the concentration defect is smaller than the structural defect. RNA at 37 ◦C in 1 M Na+.
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Figure S2: Predicted minimum free energy structure of short RNA inputs analyzed in isolation from the remainder of the full-length
mRNA. (a) Short RNA input Xs for the forward logic X aY. (b) Short RNA input Ys for the reverse logic Y aX. Nucleotide shading indicates
the probability of adopting the depicted base-pairing state at equilibrium. RNA at 37 ◦C in 1 M Na+.
S1.2 Oligonucleotide synthesis and radioactive labeling
Oligonucleotides (RNA and modified RNA) were chemically synthesized and RNase-free HPLC purified by Integrated DNA
Technologies (IDT). Strand B was labeled with 32P in order to distinguish scRNA A·B, shRNA B, and the resulting siRNA
from lysate-derived nucleic acids. After observing that 50-32P was efficiently removed in lysate (thus eliminating our ability
to image the gel), we devised a method to internally label B, which forms a hairpin in isolation from A. The hairpin was
synthesized in two pieces: B1 and B2. The location of the strand break was chosen to be contained within the final siRNA so
that the 32P would be present in the final siRNA output. B2 was 50-32P labeled. 50 µL 50-32P labeling reactions of short 30
fragment (B2, 2 µM) or siRNA markers (NEB, N2101, 5 µL) used T4 Polynucleotide Kinase (NEB, M0201) and a limiting
amount of ATP. Non-radioactive ATP (NEB, P0756) was used in combination with [-32P] ATP (10 mCi/mL, 3000 Ci/mmol,
PerkinElmer, BLU002A250UC) to ensure that the reactions contained 1 µM ATP with 10% [ -32P] ATP. Unincorporated ATP
was removed using illustra MicroSpin G-25 columns (GE Healthcare, 27-5325-01) according to manufacturer instructions.
Radioactive signal counts per minute (CPM) were measured on a Beckman liquid scintillation counter (LS 6000SC). 50-32P
labeled B2 (39 pmol) was annealed (90 ◦C for 3m, cool to 23 ◦C at 1 ◦C/m, hold 23 ◦C) to a limiting amount of B1 (25 pmol)
to form a hairpin structure with a nick in the stem (49 µL reaction, 1⇥ RNA ligase 2 buffer). Ligation with 10 units T4 RNA
Ligase 2 (NEB, M0239) resulted in a hairpin that contained 32P within the RNA backbone located approximately in the middle
of the hairpin stem. The labeled hairpin was purified by spin column chromatography (Oligo Clean & Concentrator, Zymo,
D4060). The scRNA duplex A·B was prepared by annealing 32P-labeled B to an excess of A (20 µL reaction: 1⇥ Buffer D-, 17
pmol B, 25 pmol A), separating via native PAGE (12% native TBE polyacrylamide gel, 200 V for 3 h at room temperature in 1⇥
TBE) and excising the A·B band. The scRNA duplex was eluted from the excised gel piece by crushing with a Squisher (Zymo
Research, H1001) in 1⇥ Buffer D– (20 mM HEPES, pH 7.5; 100 mM KCl; 0.2 mM EDTA, pH 8.0; 5% glycerol) followed by
an incubation at 4 ◦C overnight (or longer). The supernatant was filtered through a Nanosep MF Centrifugal Device, 0.45 µm
(Pall, ODM45C34) at 10,000 g for 3 min and stored at 4 ◦C to help retain the correct secondary structure.
S1.3 Cell lysate preparation
Human cell lysate was generated by sonication of HEK 293T cells following the method of Sakurai et al.5 Briefly, HEK 293T
(ATCC, CRL-3216) cells were grown to confluency in 10 cm dishes, trypsinized, harvested, and washed with DPBS. The
pelleted cells were re-supsended in 0.5 mL of 1⇥ Buffer D (20 mM HEPES, pH 7.5; 100 mM KCl; 0.2 mM EDTA, pH 8.0;
5% glycerol; 0.5 mM DTT; 1⇥ HALTTM Protease Inhibitor Cocktail, EDTA-free (Thermo Fisher Scientific, 78425)) per 10 cm
plate of cells. The suspended cells were lysed in either 2 mL or 5 mL Eppendorf tubes depending on volume to be lysed. A
Misonix S-4000 sonicator with a 2 mm microtip delivered six 10 s 20% amplitude pulses with 30 s breaks. The cells were kept
on ice or in a chilled metal block to prevent overheating. The lysate was cleared by centrifugation at 13,000 g for 15 min at 4
◦C and either immediately flash frozen (wildtype lysate) or immunodepleted (Dicer-depleted lysate and control lysate) and then
flash frozen. The lysate was aliquoted for single use, frozen in a dry ice/ethanol bath, and stored at –80 ◦C. Lysate total protein
concentration, used to normalize lysate per reaction, was determined in triplicate with a Pierce BCA Protein Assay kit (Thermo
Fisher Scientific, 23225) using a BSA standard by measuring A562 on a plate reader (BioTek Synergy Neo2 or equivalent).
Lysate total protein concentration was in the range of 3–5 mg/mL. For Dicer-depleted lysate, Dicer was removed from the
lysate via a two-step process: siRNA silencing of Dicer prior to lysis followed by Dicer immunodepletion after lysis. Three
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days prior to lysis, the HEK 293T cells were transfected with 20 nM Dicer siRNA (Santa Cruz Biotechnology, sc-40489) using
Lipofectamine RNAiMAX (Thermo Fisher Scientific, 13778030). The cells were lysed as described above and immunodepled
using an anti-Dicer antibody following a protocol modified from Sakurai et al.5 Briefly, immunodepletion consisted of gently
rotating 20 µg anti-Dicer antibody (abcam, ab14601) per 1 mL lysate overnight at 4 ◦C on a rotisserie rotator. 300 µL Protein
G agarose beads, high affinity (abcam, ab193258) per 1 mL lysate were washed three times in 1⇥ Buffer D, resuspended in
1⇥ Buffer D and added to the lysate. The beads and lysate were incubated for 6 h at 4 ◦C with gentle rotation. The beads
were removed by centrifugation at 1000 g for 5 min at 4 ◦C. The resulting Dicer-depleted lysate was flash frozen as described
above. Control lysate followed the same protocol except that the Dicer siRNA and anti-Dicer antibody were replaced with an
equivalent amount of buffer.
S1.4 Concentration estimates for cells and lysate
To estimate the needed siRNA concentration in vivo, note that Pei et al. measured knockdown of the target gene Ssb varying
from 50%–87% for 370–2200 copies of the siRNA guide strand per mouse liver cell.6 Most mammalian cells have a volume in
the range of 0.5–4 pL/cell.7 The lower and upper bounds on molar concentration are then estimated as:
clower =
370 molecules/cell
6.02⇥ 1023 molecules/mol · 4⇥ 10−12 L/cell = 0.15 nM,
cupper =
2200 molecules/cell
6.02⇥ 1023 molecules/mol · 0.5⇥ 10−12 L/cell = 7 nM,
corresponding to an siRNA concentration range of 0.15–7 nM for effective silencing.
To estimate the dilution factor from cells to lysate, note that our scRNA signal transduction experiments were performed in
lysate containing 1.25 µg of total protein per µL. During lysate preparation, we estimate that 5000 cells are lysed to produce
1 µg of total protein. Hence, for a cellular volume of 0.5–4 pL/cell,7 lower and upper bounds on the dilution factor are:
dlower =
1 µg
5000 cell · 4⇥ 10−12 L/cell · 1.25⇥ 106 µg/L = 40,
dupper =
1 µg
5000 cell · 0.5⇥ 10−12 L/cell · 1.25⇥ 106 µg/L = 320,
corresponding to a dilution factor of 40–320 moving from cells to lysate. Alternatively, Gillen and Forbush measured 154 µg
total protein per µL in HEK293 cells,8 yielding a dilution estimate of
dalternate =
154 µg/µL
1.25 µg/µL
= 123 (S1)
consistent with the lower and upper bounds above.
S1.5 mRNA in vitro transcription
50-capped, 30-polyadenylated mRNA was created through in vitro transcription, capping, and tailing using CellScript’s T7
mScript Standard mRNA Production System (C-MSC11610). DsRed2 and d2EGFP mRNA sequences matching those found
in our HEK293 d2EGFP + DsRed2 cell line were cloned into the pTnT vector (Promega, L5610) via Gibson assembly (NEB,
E2611). The appropriate plasmid was linearized with Spe1-HF (NEB, R3133) and used as a template in the mRNA production
system. The mRNAmass concentration (ng/µL) was determine via A260 measurements on a NanoDrop 8000 Spectrophotome-
ter (Thermo Fisher Scientific, ND-8000) assuming 1 OD at 260 nM = 40 ng/µL. Mass concentration was converted to molar
concentration via the following molecular weights: DsRed2 mRNA = 345,036 g/mol, d2EGFP mRNA = 387,342 g/mol. These
molecular weights are approximate due to variation in the length of the poly(A) tail.
S1.6 scRNA signal transduction reactions
The concentration of 50-32P labeled B2 was calculated based on the assumption that all the ATP in the labeling reaction is
consumed. This concentration can then be used to approximate scRNA concentrations by using the ratio of scRNA radioactive
signal (CPM) to the corresponding 50-32P labeled B2 radioactive signal. Unlabeled strand concentrations were calculated using
NanoDrop 8000 Spectrophotometer A260 measurements and extinction coefficients provided by IDT. Immediately prior to
signal transduction reactions:
S6
1. scRNA A·B was diluted from stock stored at 4 ◦C to 20 nM in 1⇥ Buffer D–,
2. mRNA was diluted to 100 nM in 1⇥ Buffer D– and relaxed (65 ◦C for 5 min; room temperature for ≥30 min),
3. shRNA B (to serve as a control) was snap cooled (95 ◦C at 90 s; ice for 30 s; room temperature for ≥30 min) at 20 nM
in 1⇥ Buffer D–,
4. mRNA complexed with blocker strand L (to serve as a control) was prepared by heating a mixture containing 400 nM
blocker and 100 nM mRNA in 1⇥ Buffer D– to 65 ◦C for 5 min, followed by room temperature for ≥30 min.
Signal transduction reactions were performed in 20 µL containing 25 µg cell lysate, 2.5 nM scRNA (scRNA A·B or shRNA
B), and 10 nM RNA input (either full-length mRNA, short RNA, or mRNA complexed with blocker) in 1⇥ Buffer D. Final
concentration 6.4 mM MgCl2 (Ambion, AM9530G), necessary for Dicer cleavage, and 1⇥ HALTTM protease inhibitor were
added to all reactions. Reactions were incubated at 37 ◦C for 4 h except for the gels in Figures S4, S5, S6, S12, and S13, which
were incubated for 2 h. Most reactions were immediately separated by native PAGE. For the reactions in Figures S4, S5, and
S6, the lysate proteins were removed before separation by native PAGE. Protein removal consisted of protein degradation by
adding 1 µL (⇠20 µg) Proteinase K (NEB, P8107S) and 29 µL PK buffer (200 mM Tris-HCl, pH 7.5; 25 mM EDTA; 300 mM
NaCl; 2% wt/vol sodium dodecyl sulfate)9 and incubating at 37 ◦C for 30 min. The nucleic acids were then purified using an
Oligo Clean & Concentrator kit (Zymo, D4060) and eluted in 20 µL water (10 µL water for the reactions in Figure S5).
S1.7 Native polyacrylamide gel electrophoresis
The reactions were analyzed by native PAGE using 20% TBE polyacrylamide gels run at 200 V for 8 h at room temperature in
1⇥ TBE. Samples were mixed with 5⇥ native loading dyes and the gel wells were loaded with 2,000 – 10,000 CPM (adjusted
sample volume to ensure a constant CPM per lane across the gel). Every other lane was skipped to prevent crosstalk between
lanes. Gels were exposed for approximately 24 h to a storage phosphor screen (BAS-IP) and imaged using the IP-S settings of
the FujiFilm FLA-5100 imaging system.
S1.8 Gel quantification
Quantification was performed using Multi Gauge software (FujiFilm). To calculate the ON:OFF ratio, we quantify siRNA
production in the presence of either the cognate mRNA input (ON state) or a non-cognate mRNA input (OFF state). For a
given lane containing reaction products, we calculate the mean intensity, representing a combination of signal and background,
for each of two boxes: (1) siRNA bands box and (2) full lane box. The background component is then estimated using boxes
equivalently positioned within the empty lanes on either side. siRNA production was calculated as the ratio of background-
subtracted signal in the siRNA box divided by the background-subtracted signal in the full lane box. Let x¯ON and sON denote
the sample mean and standard error for the ON state over three replicate lanes, and let x¯OFF and sOFF denote the sample mean
and standard error for the OFF state over three replicate lanes. The ON/OFF ratio is then estimated as
x¯ON/OFF = x¯ON/x¯OFF
with standard error estimated via uncertainty propagation as
sON/OFF  x¯ON
x¯OFF
s✓
sON
x¯ON
◆2
+
✓
sOFF
x¯OFF
◆2
.
This upper bound on estimated standard error holds under the assumption that the correlation between ON and OFF is non-
negative.
S1.9 RNAhyb
We followed the protocol of Section S2 to measure the accessibility of in vitro transcribed d2EGFP mRNA (input mRNA Y for
the reverse mechanism) using 20-nt DNA probes. Initially, we tested probes complementary to the mRNA at 10-nt intervals.
Additional probes were tested in regions of interest (see Table S4 for a complete list of probes).
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S2 RNAhyb protocol
The RNAhyb assay enables direct experimental measurement of the accessibility of different windows along an mRNA.
• Step 1. Unpurified DNA probes: Order unpurified short DNA probes (default: 20 nt) complementary to subsequences
along the mRNA at regular intervals (default: 10 nt).
• Step 2. Radioative labeling: Label each DNA probe with 50-32P by incubating 100 pmol probe with 20 units T4
Polynucleotide Kinase (NEB, M0201) and 0.2-0.5 µL end-labeling grade ATP -32P (MP Biomedicals, 013502002) in a
50 µL reaction volume at 37 ◦C for 1 h. Heat inactive T4 Polynucleotide Kinase by heating to 65 ◦C for 20 m. Remove
unincorporated ATP using an illustra MicroSpin G-25 column (GE Healthcare, 27-5325-01).
• Step 3. Hybridization: Incubate 2.5 nM probes with 10 nM mRNA (stock concentrations determined by A260 mea-
surements on a NanoDrop and converted to molar units using the appropriate extinction coefficient) for 2 h at 37 ◦C in
1⇥ Buffer D– supplemented with 6.4 mM MgCl2 and 1⇥ HALT protease inhibitor.
• Step 4. Native PAGE and autoradiography: Run a 4–20% native gel (BioRad, 4565056), expose to a storage phosphor
screen (BAS-IP) for approximately 24 h and image with the IP-S settings of an imagining system (e.g., FujiFilm FLA-
5100). Example gels are shown in Figures S12 and S13.
• Step 5. Quantification: Quantify the band representing the mRNA:probe complex and normalize the signal relative to
the total lane signal after background subtraction. Example hybridization yields are shown in Figure S11.
Figure S3 illustrates mRNA:probe hybridization and the expected appearance of the gel bands.
mRNA
mRNA:probe
+
probe (limiting)
a
a*
a*
= 32P
a
probe
mRNA:probe
mRNA:probe signal
   total lane signal
a  Hybridization b  Native PAGE separation
Quantification
Figure S3: RNAhyb protocol schematic. (a) Hybridization: the mRNA of interest and a limiting amount of probe are incubated together in
the relevant conditions. A separate hybridization reaction is performed for each probe. (b) Native PAGE separation: Separation of the bound
versus unbound probe by native PAGE followed by autoradiography allows for quantification of the mRNA:probe binding.
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S3 Sequences
S3.1 scRNA sequences for forward mechanism (X a Y) and reverse mechanism (Y a X)
a Forward mechanism sequences (X a Y)
Strand Domains Sequence
XS a-b-c 50-CAGCUUAUAAUGGUUACAAAUAAAGCAAUAGCAUC-30
A y-z-c*-b*-a* 50-ACUUCAAGAUCCGCCACAACAGAUGCUAUUGCUUUAUUUGUAACCAUUAUAAGCUG-30
B z-c*-b-c-z*-y* 50-UUCAAGAUCCGCCACAACAGAUGCCAAAUAAAGCAAUAGCAUCUGUUGUGGC32PGGAUCUUGAAGU-30
B1 50-UUCAAGAUCCGCCACAACAGAUGCCAAAUAAAGCAAUAGCAUCUGUUGUGGC-30
B2 50-GGAUCUUGAAGU-30
LX 3nt-a*-3nt 50-UUGUAACCAUUAUAAGCUGCAA-30
b Reverse mechanism sequences (Y a X)
Strand Domains Sequence
YS a-b-c 50-CAACGAGAAGCGCGAUCACAUGGUCCUGCUGGAGU-30
A y-z-c*-b*-a* 50-AGCAUCACAAAUUUCACAAAUACUCCAGCAGGACCAUGUGAUCGCGCUUCUCGUUG-30
B z-c*-b-c-z*-y* 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGCU-30
B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
B2 50-GAAAUUUGUGAUGCU-30
LY 3nt-a*-3nt 50-GUGAUCGCGCUUCUCGUUGGGG-30
Table S1: scRNA sequences. (a) Forward mechanism (X a Y). (b) Reverse mechanism (Y a X). Sequences constrained by mRNA X
(DsRed2) are shown in magenta; sequences constrained by mRNA Y (d2EGFP) are shown in green. Domain lengths: |a| = 16, |b| = 14, |c| =
5, |y| = 2, |z| = 19. Underlined nucleotides are 20OMe-RNA; all other nucleotides are RNA. B oligonucleotides were constructed via ligation
of B1 and 50-32P labeled B2 to incorporate 32P into the backbone of B at the depicted location.
S3.2 mRNA sequences (X and Y)
The mRNA sequences were cloned into the pTnT vector for transcription with T7. The sequences were determined by isolating
and sequencing mRNA from an HEK293 d2EGFP + DsRed2 cell line created in lab through genomic integration of pDsRed2-
C1 (Clontech, PT3603-5, 632407) in HEK293 d2EGFP cells (gift from C. Beisel).
mRNA X: DsRed2
Nucleotides highlighted in magenta indicate the subsequence that the NUPACK sequence designer selected for detection by the
scRNA for the forward mechanism (X a Y).
1 GGUCAGAUCC GCUAGCGCUA CCGGUCGCCA CCAUGGCCUC CUCCGAGAAC GUCAUCACCG AGUUCAUGCG
71 CUUCAAGGUG CGCAUGGAGG GCACCGUGAA CGGCCACGAG UUCGAGAUCG AGGGCGAGGG CGAGGGCCGC
141 CCCUACGAGG GCCACAACAC CGUGAAGCUG AAGGUGACCA AGGGCGGCCC CCUGCCCUUC GCCUGGGACA
211 UCCUGUCCCC CCAGUUCCAG UACGGCUCCA AGGUGUACGU GAAGCACCCC GCCGACAUCC CCGACUACAA
281 GAAGCUGUCC UUCCCCGAGG GCUUCAAGUG GGAGCGCGUG AUGAACUUCG AGGACGGCGG CGUGGCGACC
351 GUGACCCAGG ACUCCUCCCU GCAGGACGGC UGCUUCAUCU ACAAGGUGAA GUUCAUCGGC GUGAACUUCC
421 CCUCCGACGG CCCCGUGAUG CAGAAGAAGA CCAUGGGCUG GGAGGCCUCC ACCGAGCGCC UGUACCCCCG
491 CGACGGCGUG CUGAAGGGCG AGACCCACAA GGCCCUGAAG CUGAAGGACG GCGGCCACUA CCUGGUGGAG
561 UUCAAGUCCA UCUACAUGGC CAAGAAGCCC GUGCAGCUGC CCGGCUACUA CUACGUGGAC GCCAAGCUGG
631 ACAUCACCUC CCACAACGAG GACUACACCA UCGUGGAGCA GUACGAGCGC ACCGAGGGCC GCCACCACCU
701 GUUCCUGAGA UCUCGAGCUC AAGCUUCGAA UUCUGCAGUC GACGGUACCG CGGGCCCGGG AUCCACCGGA
771 UCUAGAUAAC UGAUCAUAAU CAGCCAUACC ACAUUUGUAG AGGUUUUACU UGCUUUAAAA AACCUCCCAC
841 ACCUCCCCCU GAACCUGAAA CAUAAAAUGA AUGCAAUUGU UGUUGUUAAC UUGUUUAUUG CAGCUUAUAA
911 UGGUUACAAA UAAAGCAAUA GCAUCACAAA UUUCACAAAU AAAGCAUUUU UUUCACUGCA AAAAAAAAAA
981 AAAAAAAAAA AAAAAAAAAC UAG
S9
mRNA Y: d2EGFP
Nucleotides highlighted in yellow indicate the accessible window identified using RNAhyb and supplied to the NUPACK se-
quence designer for design of the reverse mechanism (Y a X); nucleotides in green indicate the subsequence that the designer
selected for detection by the scRNA.
1 GAGAACCCAC UGCUUACUGG CUUAUCGAAA UUAAUACGAC UCACUAUAGG GAGACCCAAG CUGGCUAGCG
71 UUUAAACUUA AGCUUGGUAC CCGCCACCAU GGUGAGCAAG GGCGAGGAGC UGUUCACCGG GGUGGUGCCC
141 AUCCUGGUCG AGCUGGACGG CGACGUAAAC GGCCACAAGU UCAGCGUGUC CGGCGAGGGC GAGGGCGAUG
211 CCACCUACGG CAAGCUGACC CUGAAGUUCA UCUGCACCAC CGGCAAGCUG CCCGUGCCCU GGCCCACCCU
281 CGUGACCACC CUGACCUACG GCGUGCAGUG CUUCAGCCGC UACCCCGACC ACAUGAAGCA GCACGACUUC
351 UUCAAGUCCG CCAUGCCCGA AGGCUACGUC CAGGAGCGCA CCAUCUUCUU CAAGGACGAC GGCAACUACA
421 AGACCCGCGC CGAGGUGAAG UUCGAGGGCG ACACCCUGGU GAACCGCAUC GAGCUGAAGG GCAUCGACUU
491 CAAGGAGGAC GGCAACAUCC UGGGGCACAA GCUGGAGUAC AACUACAACA GCCACAACGU CUAUAUCAUG
561 GCCGACAAGC AGAAGAAUGG CAUCAAGGUG AACUUCAAGA UCCGCCACAA CAUCGAGGAC GGCAGCGUGC
631 AGCUCGCCGA CCACUACCAG CAGAACACCC CCAUCGGCGA CGGCCCCGUG CUGCUGCCCG ACAACCACUA
701 CCUGAGCACC CAGUCCGCCC UGAGCAAAGA CCCCAACGAG AAGCGCGAUC ACAUGGUCCU GCUGGAGUUC
771 GUGACCGCCG CCGGGAUCAC UCUCGGCAUG GACGAGCUGU ACAAGAAGCU UAGCCAUGGC UUCCCGCCGG
841 AGGUGGAGGA GCAGGAUGAU GGCACGCUGC CCAUGUCUUG UGCCCAGGAG AGCGGGAUGG ACCGUCACCC
911 UGCAGCCUGU GCUUCUGCUA GGAUCAAUGU GUAGCUCGAG UCUAGAGGGC CCGUUUAAAC CCGCUGAUCA
981 GCCUCGACUG UGCCUUCUAG UUGCCAGCCA UCUGUUGUUU GCCCCUCCCC CGUGCCUUCC UUGACCCUGG
1051 AAGGUGCCAC UCCCACUGUC CUUUCCUAAU AAAAUGAGGA AAUUGCAUCG CAAAAAAAAA AAAAAAAAAA
1121 AAAAAAAAAA ACUAG
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S4 Motivating failures
S4.1 scRNA not functional with full-length mRNA input at low concentration in buffer or lysate
(cf. Reference 1)
In Reference 1 (scRNA Mechanism 3), the scRNA that provided the starting point for the present work (see sequences in
Table S2) was tested at 500 nM scRNA concentration in buffer (100 mM potassium acetate, 20 mM HEPES, pH 7.5; 37 ◦C
for 2 h) with either a short RNA input Xs at 1⇥ or a full-length mRNA input X at 2⇥ (to account for uncertainties in mRNA
concentration determination). Quantification of conditional production of shRNA B revealed an undetectable OFF state in the
absence of an RNA input (i.e., smaller than the gel quantification uncertainty) and a strong ON state in the presence of either
short RNA input Xs (> 200-fold increase) or full-length mRNA input X (> 50-fold increase).
Here, when the same scRNAs were tested at a lower 2.5 nM scRNA concentration in Buffer D– (20 mM HEPES, pH 7.5;
100 mM KCl; 0.2 mM EDTA, pH 8.0; 5% glycerol; 37 ◦C for 2 h) with RNA input at 4⇥, we observed strong conditional
production of shRNA B in response to the short RNA input Xs but minimal production in response to full-length mRNA input
X (Figure S4a). Furthermore, with the scRNA at 2.5 nM in 1.25 µg/µL of control lysate (37 ◦C for 2 h), there was diminished
production of shRNA B in response to short RNA input Xs and negligible production in response to full-length mRNA input X
(Figure S4b).
This loss of performance motivated domain redimensioning to recover scRNA performance using a full-length mRNA input
at low concentration in lysate. Through multiple rounds of computational sequence design and experimental testing, we made
the following modifications to the scRNA domain dimensions:
• increase toehold ‘a’ by 4 nt to improve nucleation with the full-length mRNA input,
• increase internal toeholds ‘c’ and ‘c*’ by 2 nt to improve self-nucleation within B during the hybridization cascade that
leads to the formation of the shRNA Dicer substrate upon binding of scRNA A·B to mRNA input X
• addition of 2-nt duplex ‘y/y*’ to A·B to improve the OFF state (reduce spontaneous production of shRNA B in the
absence of mRNA input X)
The redimensioned scRNA sequences for the forward mechanism (X a Y) are shown in Table S1a and are characterized in
Figure 3a and 5.
scRNA tested in Figure S4
Strand Domains Sequence
Xs a-b-c 50-UGGGAGCGCGUGAUGAACUUCGAGGACGG-30
A z-c*-b*-a* 50-UUCAUCUGCACCACCGGCACCGUCCUCGAAGUUCAUCACGCGCUCCCA-30
B z-c*-b-c-z*-y* 50-UUCAUCUGCACCACCGGCACCGAUGAACUUCGAGGACGGUGCC32PGGUGGUGCAGAUGAACU-30
B1 50-UUCAUCUGCACCACCGGCACCGAUGAACUUCGAGGACGGUGCC-30
B2 50-GGUGGUGCAGAUGAACU-30
Table S2: Sequences for the previously studied scRNA of Reference 1. Sequences constrained by mRNA X (DsRed2) are shown in
magenta; sequences constrained by mRNA Y (d2EGFP) are shown in green. Domain lengths: |a| = 12, |b| = 14, |c| = 3, |y| = 2, |z| = 19.
Underlined nucleotides are 20OMe-RNA; all other nucleotides are RNA. B oligonucleotides were constructed via ligation of B1 and 50-32P
labeled B2 to incorporate 32P into the backbone of B at the depicted location.
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Figure S4: Testing previously studied scRNA at low concentration in buffer and lysate. The scRNA of Reference 1 (Mechanism 3) was
tested at 2.5 nM in 1⇥ Buffer D– (panel a) or 1.25 µg/µL control lysate (panel b). Experimental conditions: sequences of Table S2, strand
B labeled with 32P, reaction at 37◦C for 2 h, 4⇥ short RNA input Xs or full-length mRNA input X, separated via native PAGE after protein
removal. With short RNA input Xs, production of shRNA B is nearly complete in buffer but reduced in lysate (lane 4). With full-length
mRNA input X, production of shRNA B is minimal in buffer and negligible in lysate (lane 5). In lysate, the observed minimal processing of
shRNA B into siRNAs could indicate that B is a poor Dicer substrate or that this batch of lysate has low Dicer activity.
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S4.2 scRNAs functional in lysate for short RNA inputs but not full-length mRNA inputs
When designing the reverse mechanism (Y a X), we repeatedly encountered a situation where the designed scRNAs sequences
functioned well in lysate, achieving strong conditional production of siRNA output anti-X when presented with short RNA
input Ys but not when presented with the full-length mRNA input Y. Sequences for two example designs with this property
are shown in Table S3 and characterized in Figures S5 and S6. These difficulties resulting from the unpredictability of mRNA
accessibility motivated the development of the RNAhyb assay (Section S2) to experimentally determine accessible windows
within the full-length mRNA, which are then provided to the NUPACK designer as sequence constraints.
a scRNA tested in Figure S5
Strand Domains Sequence
Ys a-b-c 50-AAGGACGACGGCAACUACAAGACCCGCGCCGAGGU-30
A y-z-c*-b*-a* 50-UAGCAUCACAAAUUUCACAAAACCUCGGCGCGGGUCUUGUAGUUGCCGUCGUCCUU-30
B z-c*-b-c-z*-y* 50-GCAUCACAAAUUUCACAAAACCUCACAAGACCCGCGCCGAGGUUUUGUGAA32PAUUUGUGAUGCUA-30
B1 50-GCAUCACAAAUUUCACAAAACCUCACAAGACCCGCGCCGAGGUUUUGUGAA-30
B2 50-AUUUGUGAUGCUA-30
b scRNA tested in Figure S6
Strand Domains Sequence
Ys a-b-c 50-CAUGUCUUGUGCCCAGGAGAGCGGGAUGGACCGUC-30
A y-z-c*-b*-a* 50-AUCACAAAUUUCACAAAUAAAGACGGUCCAUCCCGCUCUCCUGGGCACAAGACAUG-30
B z-c*-b-c-z*-y* 50-CACAAAUUUCACAAAUAAAGACGGGAGAGCGGGAUGGACCGUCUUUAUUUG32PUGAAAUUUGUGAU-30
B1 50-CACAAAUUUCACAAAUAAAGACGGGAGAGCGGGAUGGACCGUCUUUAUUUG-30
B2 50-UGAAAUUUGUGAU-30
Table S3: Sequences for scRNAs that function in lysate for short RNA inputs but not full-length mRNA inputs. Sequences constrained
by mRNA X (DsRed2) are shown in magenta; sequences constrained by mRNA Y (d2EGFP) are shown in green. Domain lengths: |a| =
16, |b| = 14, |c| = 5, |y| = 2, |z| = 19. Underlined nucleotides are 20OMe-RNA; all other nucleotides are RNA. B oligonucleotides were
constructed via ligation of B1 and 50-32P labeled B2 to incorporate 32P into the backbone of B at the depicted location.
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Figure S5: Example 1 of a preliminary reverse mechanism (Y a X) design where scRNA A·B responds to short RNA input Ys but not
full-length mRNA input Y. Experimental conditions: scRNA at 2.5 nM, sequences of Table S3a, strand B labeled with 32P, 4⇥ short RNA
input Ys or full-length mRNA input Y, reaction at 37 ◦C for 2 h in 1.25 µg/µL Dicer-depleted or wildtype lysate, separated via native PAGE
after protein removal. Short RNA input Ys triggers strong shRNA production in Dicer-depleted lysate (lane 3) and strong siRNA production
in wildtype lysate (lane 4), but full-length mRNA input Y yields only weak shRNA and siRNA production (lanes 5 and 6); scRNA A·B
predominantly does not bind to mRNA Y (lanes 5 and 6).
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Figure S6: Example 2 of a preliminary reverse mechanism (Y a X) design where scRNA A·B responds to short RNA input Ys but not
full-length mRNA input Y. Experimental conditions: scRNA at 2.5 nM, sequences of Table S3b, strand B labeled with 32P, 4⇥ short RNA
input Ys or full-length mRNA input Y, reaction at 37 ◦C for 2 h in 1⇥ Buffer D– (panel a) or 1.25 µg/µL wildtype lysate (panel b), separated
via native PAGE after protein removal (reactions run in buffer were treated with the same conditions for consistency). scRNA A·B incubated
with the short detection target Ys produces shRNA B in buffer (lane 2) and siRNAs in lysate (lane 6), but A·B incubated with the full-length
mRNA Y produces minimal shRNA B in buffer (lane 3) and negligible siRNA in lysate (lane 7).
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S5 Additional scRNA signal transduction studies for forward and reverse mecha-
nisms
Here, we present additional signal transduction controls for the forward mechanism (X a Y) and reverse mechanism (Y a X):
• Figure S7 displays stepping gels at high concentration (500 nM scRNA, 4⇥ short RNA input) so that SYBR Gold staining
can be used to image all strands.
• Figure S8 compares performance in Dicer-depleted lysate and in control lysate that undergoes the same preparation steps
as the Dicer-depleted lysate (leaving out the Dicer siRNA and anti-Dicer antibody). scRNA performance in the control
lysate is comparable to that in wildtype lysate (Figure 3), suggesting that the observed differences in Dicer processing
between Dicer-depleted lysate and wildtype lysate are not an artifact of differences in lysate preparation steps.
• Figure S9 verifies that blocker strands do not interfere with scRNA performance, except via binding to the cognate mRNA
input.
• Figure S10 provides replicates for quantification of conditional siRNA production.
S5.1 Stepping gels for forward and reverse mechanisms at high concentration in buffer with stain-
ing of all RNA species (cf. Figure 3)
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Figure S7: Stepping gels for forward and reverse mechanisms at high concentration in buffer with staining of all RNA species
(cf. Figure 3). (a) Forward mechanism (X a Y). (b) Reverse mechanism (Y a X). Experimental conditions: scRNA at 500 nM, sequences
of Table S1, 4⇥ short RNA input Xs or Ys, reaction at 37 ◦C for 4 h in 1⇥ Buffer D–, separated via native PAGE, bands stained with SYBR
Gold. A, B, Xs and Ys serve as size markers (lanes 1–3). The scRNA duplex A·B forms a single band and no B is visible after the 4 h reaction
(lane 4). Incubation of A with the cognate short RNA input (lane 5) yields duplex Xs·A (panel a) or Ys·A (panel b). Incubation of scRNA
A·B with the cognate short RNA input (lane 6) yields the shRNA B and duplex Xs·A (panel a) or Ys·A (panel b) as well as a higher band that
is likely the trimer Xs·A·B (panel a) or Ys·A·B (panel b).
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S5.2 Stepping gels for forward and reverse mechanisms in Dicer-depleted and control lysates
(cf. Figure 3)
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Figure S8: Stepping gels for forward and reverse mechanisms in Dicer-depleted and control lysates (cf. Figure 3). (a) Forward
mechanism (X a Y). (b) Reverse mechanism (Y a X). Experimental conditions: scRNA at 2.5 nM, sequences of Table S1, strand B labeled
with 32P, 4⇥ full-length mRNA input X (panel a) or Y (panel b), input mRNA pre-incubated with 20OMe-RNA blocker strand for Blocked
reactions, reaction at 37 ◦C for 4 h in 1.25 µg/µL Dicer-depleted lysate or control lysate (contains Dicer), separated via native PAGE. OFF
state: in the absence of input mRNA, scRNA A·B is stable with minimal production of shRNA B Dicer substrate (lane 1) or siRNA following
Dicer processing (lane 2). ON state: in the presence of the input mRNA, there is strong production of shRNA B (lane 3) and siRNA (lane
4). Blocked state: in the presence of a blocker strand that binds to the mRNA input at the scRNA nucleation site, the system is restored to
the OFF sate (lanes 5, 6), indicating that the scRNA:mRNA interaction occurs at the intended location on the mRNA. shRNA B (lanes 7, 8)
serves as a control for Dicer cleavage. The results in the control lysate are comparable to those obtained in wildtype lysate (Figure 3), with
somewhat reduced Dicer efficiency for the reverse mechanism (lane 8 of panel b).
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S5.3 Orthogonality gels for forward and reverse mechanisms with blocker strands (cf. Figures 3
and 5)
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Figure S9: Orthogonality gels for forward and reverse mechanisms with blocker strands (cf. Figures 3 and 5). Blocker strands (LX for
mRNA input X for the forward mechanism, LY for mRNA input Y for the reverse mechanism) are complementary to the mRNA subsequence
that serves as a nucleation site for the scRNA A·B. In lanes 1–4, the mRNA input is pre-incubated with the non-cognate blocker strand (X
with LY, Y with LX); in lanes 5-6, the mRNA input is pre-incubated with the cognate clocker strand (X with LX, Y with LY). Experimental
conditions: scRNAs at 2.5 nM, sequences of Table S1, B strands labeled with 32P, 4⇥ full-length mRNA input X or Y, input mRNA pre-
incubated with indicated 20OMe-RNA blocker strand, reaction at 37 ◦C for 4 h in 1.25 µg/µL wildtype lysate (containing endogenous Dicer),
separated via native PAGE. As expected, the non-cognate blocker strands do not significantly alter the ability of the cognate mRNA input
to trigger siRNA production (forward mechanism, lane 1; reverse mechanism, lane 4). Furthermore, the non-cognate blocker strands do not
significantly alter the inability of the non-cognate mRNA input to trigger siRNA production (forward mechanism, lane 2; reverse mechanism,
lane 3).
S5.4 Orthogonality gel replicates for forward and reverse mechanisms in lysate (cf. Figure 5)
Replicate #1 Replicate #2 Replicate #3
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Figure S10: Orthogonality gel replicates for forward and reverse mechanisms in lysate (cf. Figure 5). Conditional siRNA production
in the presence of cognate mRNA input (ON state) or non-cognate mRNA input (OFF state) for forward logic (X a Y: cognate mRNA input
X, siRNA output anti-Y, non-cognate mRNA input Y) and reverse logic (Y a X: cognate mRNA input Y, siRNA output anti-X, non-cognate
mRNA input X). Experimental conditions: scRNAs at 2.5 nM, sequences of Table S1, B strands labeled with 32P, 4⇥ full-length mRNA
input X or Y, reaction at 37 ◦C for 4 h in 1.25 µg/µL wildtype lysate (containing endogenous Dicer), separated via native PAGE. OFF state:
minimal siRNA production in the presence of non-cognate mRNA input (lanes 2 and 3). ON state: strong production in the presence of
cognate mRNA input (lanes 1 and 4).
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S6 RNAhyb studies
Here, we present RNAhyb studies (protocol of Section S2) that were used to identify accessible subsequences of mRNA input
Y to provide to the NUPACK designer as sequence constraints when designing the scRNA sequences for the reverse mechanism
(Y a X):
• Table S4 presents 20-nt mRNA subsequences, the complementary 20-nt DNA probe sequences, and the probe hybridiza-
tion yield for 1–3 replicate gels. Figure S11 provides an expanded view of the data from Figure 4 in the main text,
depicting the probe hybridization yield for each probe, as well as the mRNA window provided to the NUPACK designer
following inspection of the RNAhyb data, and the scRNA binding site selected by NUPACK within this window. Probe
hybridization yields ranged from 0 to ⇡40%, indicating the challenge of detecting short subsequences in the context of a
full-length mRNA. Accessibility in vivo may differ due to the presence of RNA-binding proteins and helicase activity.10
• Figures S12 and S13 demonstrate the appearance of typical RNAhyb gels.
• Figure S14 compares probe hybridization yield experimental data to three types of mRNA accessibility predictions cal-
culated using NUPACK. To reduce overall experimental effort, these data suggest the approach of first computationally
screening the mRNA subsequences to identify those with low subsequence free energy (corresponding to minimal pre-
dicted secondary structure), and then using the RNAhyb assay to experimentally identify accessible windows from within
this reduced set of subsequences.
The RNAhyb assay employs DNA probes rather than RNA or 20OMe-RNA probes due to the much lower cost of DNA syn-
thesis. However, DNA:RNA base-pairing11 is weaker than RNA:RNA base-pairing12 and 20OMe-RNA:RNA base-pairing,13 so
mRNA:probe binding should provide a conservative estimate of mRNA accessibility.
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S6.1 mRNA subsequences, probe sequences, and probe hybridization yields
Start Fraction probe bound
position mRNA window sequence DNA probe sequence Rep 1 Rep 2 Rep 3
1 GAGAACCCACUGCUUACUGG CCAGTAAGCAGTGGGTTCTC 0.06
11 UGCUUACUGGCUUAUCGAAA TTTCGATAAGCCAGTAAGCA 0.02
21 CUUAUCGAAAUUAAUACGAC GTCGTATTAATTTCGATAAG 0.01
31 UUAAUACGACUCACUAUAGG CCTATAGTGAGTCGTATTAA 0.01
41 UCACUAUAGGGAGACCCAAG CTTGGGTCTCCCTATAGTGA 0.02
51 GAGACCCAAGCUGGCUAGCG CGCTAGCCAGCTTGGGTCTC 0.05
61 CUGGCUAGCGUUUAAACUUA TAAGTTTAAACGCTAGCCAG 0.02
71 UUUAAACUUAAGCUUGGUAC GTACCAAGCTTAAGTTTAAA 0.00
81 AGCUUGGUACCCGCCACCAU ATGGTGGCGGGTACCAAGCT 0.07
91 CCGCCACCAUGGUGAGCAAG CTTGCTCACCATGGTGGCGG 0.01
101 GGUGAGCAAGGGCGAGGAGC GCTCCTCGCCCTTGCTCACC 0.07
111 GGCGAGGAGCUGUUCACCGG CCGGTGAACAGCTCCTCGCC 0.01
121 UGUUCACCGGGGUGGUGCCC GGGCACCACCCCGGTGAACA 0.00
131 GGUGGUGCCCAUCCUGGUCG CGACCAGGATGGGCACCACC 0.00
141 AUCCUGGUCGAGCUGGACGG CCGTCCAGCTCGACCAGGAT 0.00
151 AGCUGGACGGCGACGUAAAC GTTTACGTCGCCGTCCAGCT 0.00
161 CGACGUAAACGGCCACAAGU ACTTGTGGCCGTTTACGTCG 0.00
171 GGCCACAAGUUCAGCGUGUC GACACGCTGAACTTGTGGCC 0.00
181 UCAGCGUGUCCGGCGAGGGC GCCCTCGCCGGACACGCTGA 0.00
191 CGGCGAGGGCGAGGGCGAUG CATCGCCCTCGCCCTCGCCG 0.00
201 GAGGGCGAUGCCACCUACGG CCGTAGGTGGCATCGCCCTC 0.00
211 CCACCUACGGCAAGCUGACC GGTCAGCTTGCCGTAGGTGG 0.03
221 CAAGCUGACCCUGAAGUUCA TGAACTTCAGGGTCAGCTTG 0.01
231 CUGAAGUUCAUCUGCACCAC GTGGTGCAGATGAACTTCAG 0.02
241 UCUGCACCACCGGCAAGCUG CAGCTTGCCGGTGGTGCAGA 0.02
251 CGGCAAGCUGCCCGUGCCCU AGGGCACGGGCAGCTTGCCG 0.01
261 CCCGUGCCCUGGCCCACCCU AGGGTGGGCCAGGGCACGGG 0.00
271 GGCCCACCCUCGUGACCACC GGTGGTCACGAGGGTGGGCC 0.01
281 CGUGACCACCCUGACCUACG CGTAGGTCAGGGTGGTCACG 0.02
291 CUGACCUACGGCGUGCAGUG CACTGCACGCCGTAGGTCAG 0.00
301 GCGUGCAGUGCUUCAGCCGC GCGGCTGAAGCACTGCACGC 0.00
311 CUUCAGCCGCUACCCCGACC GGTCGGGGTAGCGGCTGAAG 0.14 0.16
321 UACCCCGACCACAUGAAGCA TGCTTCATGTGGTCGGGGTA 0.11 0.11
331 ACAUGAAGCAGCACGACUUC GAAGTCGTGCTGCTTCATGT 0.00
341 GCACGACUUCUUCAAGUCCG CGGACTTGAAGAAGTCGTGC 0.01
351 UUCAAGUCCGCCAUGCCCGA TCGGGCATGGCGGACTTGAA 0.01
361 CCAUGCCCGAAGGCUACGUC GACGTAGCCTTCGGGCATGG 0.01
371 AGGCUACGUCCAGGAGCGCA TGCGCTCCTGGACGTAGCCT 0.01
381 CAGGAGCGCACCAUCUUCUU AAGAAGATGGTGCGCTCCTG 0.04
391 CCAUCUUCUUCAAGGACGAC GTCGTCCTTGAAGAAGATGG 0.02
401 CAAGGACGACGGCAACUACA TGTAGTTGCCGTCGTCCTTG 0.08
411 GGCAACUACAAGACCCGCGC GCGCGGGTCTTGTAGTTGCC 0.11 0.11
421 AGACCCGCGCCGAGGUGAAG CTTCACCTCGGCGCGGGTCT 0.02
431 CGAGGUGAAGUUCGAGGGCG CGCCCTCGAACTTCACCTCG 0.01
441 UUCGAGGGCGACACCCUGGU ACCAGGGTGTCGCCCTCGAA 0.00
451 ACACCCUGGUGAACCGCAUC GATGCGGTTCACCAGGGTGT 0.02
461 GAACCGCAUCGAGCUGAAGG CCTTCAGCTCGATGCGGTTC 0.00
471 GAGCUGAAGGGCAUCGACUU AAGTCGATGCCCTTCAGCTC 0.03
481 GCAUCGACUUCAAGGAGGAC GTCCTCCTTGAAGTCGATGC 0.02
491 CAAGGAGGACGGCAACAUCC GGATGTTGCCGTCCTCCTTG 0.03
501 GGCAACAUCCUGGGGCACAA TTGTGCCCCAGGATGTTGCC 0.00
511 UGGGGCACAAGCUGGAGUAC GTACTCCAGCTTGTGCCCCA 0.02
521 GCUGGAGUACAACUACAACA TGTTGTAGTTGTACTCCAGC 0.06
531 AACUACAACAGCCACAACGU ACGTTGTGGCTGTTGTAGTT 0.06
541 GCCACAACGUCUAUAUCAUG CATGATATAGACGTTGTGGC 0.04
551 CUAUAUCAUGGCCGACAAGC GCTTGTCGGCCATGATATAG 0.03
561 GCCGACAAGCAGAAGAAUGG CCATTCTTCTGCTTGTCGGC 0.05
571 AGAAGAAUGGCAUCAAGGUG CACCTTGATGCCATTCTTCT 0.02
581 CAUCAAGGUGAACUUCAAGA TCTTGAAGTTCACCTTGATG 0.04
591 AACUUCAAGAUCCGCCACAA TTGTGGCGGATCTTGAAGTT 0.08
601 UCCGCCACAACAUCGAGGAC GTCCTCGATGTTGTGGCGGA 0.08
611 CAUCGAGGACGGCAGCGUGC GCACGCTGCCGTCCTCGATG 0.02
621 GGCAGCGUGCAGCUCGCCGA TCGGCGAGCTGCACGCTGCC 0.00
631 AGCUCGCCGACCACUACCAG CTGGTAGTGGTCGGCGAGCT 0.09
641 CCACUACCAGCAGAACACCC GGGTGTTCTGCTGGTAGTGG 0.38 0.28
651 CAGAACACCCCCAUCGGCGA TCGCCGATGGGGGTGTTCTG 0.16 0.22
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Start Fraction probe bound
position mRNA window sequence DNA probe sequence Rep 1 Rep 2 Rep 3
661 CCAUCGGCGACGGCCCCGUG CACGGGGCCGTCGCCGATGG 0.02
666 GGCGACGGCCCCGUGCUGCU AGCAGCACGGGGCCGTCGCC 0.04
671 CGGCCCCGUGCUGCUGCCCG CGGGCAGCAGCACGGGGCCG 0.01 0.04
676 CCGUGCUGCUGCCCGACAAC GTTGTCGGGCAGCAGCACGG 0.13
681 CUGCUGCCCGACAACCACUA TAGTGGTTGTCGGGCAGCAG 0.14 0.13
686 GCCCGACAACCACUACCUGA TCAGGTAGTGGTTGTCGGGC 0.15
691 ACAACCACUACCUGAGCACC GGTGCTCAGGTAGTGGTTGT 0.13 0.17 0.25
696 CACUACCUGAGCACCCAGUC GACTGGGTGCTCAGGTAGTG 0.21
701 CCUGAGCACCCAGUCCGCCC GGGCGGACTGGGTGCTCAGG 0.27 0.26
706 GCACCCAGUCCGCCCUGAGC GCTCAGGGCGGACTGGGTGC 0.25
711 CAGUCCGCCCUGAGCAAAGA TCTTTGCTCAGGGCGGACTG 0.09 0.13
716 CGCCCUGAGCAAAGACCCCA TGGGGTCTTTGCTCAGGGCG 0.25
721 UGAGCAAAGACCCCAACGAG CTCGTTGGGGTCTTTGCTCA 0.13 0.10
726 AAAGACCCCAACGAGAAGCG CGCTTCTCGTTGGGGTCTTT 0.15
731 CCCCAACGAGAAGCGCGAUC GATCGCGCTTCTCGTTGGGG 0.09 0.14
734 CAACGAGAAGCGCGAUCACA TGTGATCGCGCTTCTCGTTG 0.10
736 ACGAGAAGCGCGAUCACAUG CATGTGATCGCGCTTCTCGT 0.06
741 AAGCGCGAUCACAUGGUCCU AGGACCATGTGATCGCGCTT 0.04
751 ACAUGGUCCUGCUGGAGUUC GAACTCCAGCAGGACCATGT 0.00
761 GCUGGAGUUCGUGACCGCCG CGGCGGTCACGAACTCCAGC 0.01
771 GUGACCGCCGCCGGGAUCAC GTGATCCCGGCGGCGGTCAC 0.00
781 CCGGGAUCACUCUCGGCAUG CATGCCGAGAGTGATCCCGG 0.00
791 UCUCGGCAUGGACGAGCUGU ACAGCTCGTCCATGCCGAGA 0.00
801 GACGAGCUGUACAAGAAGCU AGCTTCTTGTACAGCTCGTC 0.01
811 ACAAGAAGCUUAGCCAUGGC GCCATGGCTAAGCTTCTTGT 0.01
821 UAGCCAUGGCUUCCCGCCGG CCGGCGGGAAGCCATGGCTA 0.04
831 UUCCCGCCGGAGGUGGAGGA TCCTCCACCTCCGGCGGGAA 0.00
841 AGGUGGAGGAGCAGGAUGAU ATCATCCTGCTCCTCCACCT 0.03
851 GCAGGAUGAUGGCACGCUGC GCAGCGTGCCATCATCCTGC 0.00
861 GGCACGCUGCCCAUGUCUUG CAAGACATGGGCAGCGTGCC 0.00
871 CCAUGUCUUGUGCCCAGGAG CTCCTGGGCACAAGACATGG 0.01
881 UGCCCAGGAGAGCGGGAUGG CCATCCCGCTCTCCTGGGCA 0.04
891 AGCGGGAUGGACCGUCACCC GGGTGACGGTCCATCCCGCT 0.01
901 ACCGUCACCCUGCAGCCUGU ACAGGCTGCAGGGTGACGGT 0.01
911 UGCAGCCUGUGCUUCUGCUA TAGCAGAAGCACAGGCTGCA 0.00
921 GCUUCUGCUAGGAUCAAUGU ACATTGATCCTAGCAGAAGC 0.03
931 GGAUCAAUGUGUAGCUCGAG CTCGAGCTACACATTGATCC 0.01
941 GUAGCUCGAGUCUAGAGGGC GCCCTCTAGACTCGAGCTAC 0.05
951 UCUAGAGGGCCCGUUUAAAC GTTTAAACGGGCCCTCTAGA 0.04
961 CCGUUUAAACCCGCUGAUCA TGATCAGCGGGTTTAAACGG 0.05
971 CCGCUGAUCAGCCUCGACUG CAGTCGAGGCTGATCAGCGG 0.03
981 GCCUCGACUGUGCCUUCUAG CTAGAAGGCACAGTCGAGGC 0.01
991 UGCCUUCUAGUUGCCAGCCA TGGCTGGCAACTAGAAGGCA 0.01
1001 UUGCCAGCCAUCUGUUGUUU AAACAACAGATGGCTGGCAA 0.04
1011 UCUGUUGUUUGCCCCUCCCC GGGGAGGGGCAAACAACAGA 0.15 0.22
1021 GCCCCUCCCCCGUGCCUUCC GGAAGGCACGGGGGAGGGGC 0.08
1031 CGUGCCUUCCUUGACCCUGG CCAGGGTCAAGGAAGGCACG 0.04
1041 UUGACCCUGGAAGGUGCCAC GTGGCACCTTCCAGGGTCAA 0.04
1051 AAGGUGCCACUCCCACUGUC GACAGTGGGAGTGGCACCTT 0.11 0.25
1061 UCCCACUGUCCUUUCCUAAU ATTAGGAAAGGACAGTGGGA 0.13 0.11
1071 CUUUCCUAAUAAAAUGAGGA TCCTCATTTTATTAGGAAAG 0.01
1081 AAAAUGAGGAAAUUGCAUCG CGATGCAATTTCCTCATTTT 0.08 0.05
Table S4: RNAhyb sequences and mRNA:probe hybridization yields for mRNA Y (d2EGFP). Columns: window start position within
mRNA, mRNAwindow sequence, DNA probe sequence (complementary to mRNAwindow), and fraction of probe bound for up to 3 replicate
experiments. The 32P-labeled DNA probe is the limiting species (DNA probe = 2.5 nM, mRNA = 10 nM). Generally, the probes with the
best binding were included in replicate experiments. For some probes with higher yield, there is significant variation between replicates,
suggesting high sensitivity to experimental conditions. Sequences listed 50 to 30.
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Figure S11: RNAhyb fraction of probe bound for mRNA Y (d2EGFP). Each plotted line depicts the location of a probe along the mRNA
(abscissa) and the fraction of probe bound to the mRNA (ordinate). The 32P-labeled DNA probe is the limiting species (DNA probe = 2.5
nM, mRNA = 10 nM). All probes were tested at least once, with some probes tested up to three times. The region between 676 and 769
(medium blue shading) was provided to the NUPACK designer as an accessible window when designing the reverse mechanism (Y a X). The
light blue shading indicates the mRNA window selected by NUPACK for scRNA binding.
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S6.2 Example gels demonstrating range of probe hybridization yields
Probe start position: 391 411 431 451 471
0.02 0.11 0.01 0.03Fraction probe bound: 0.02
mRNA: probe 
probe 
Figure S12: Example RNAhyb gel 1. For each probe, the mRNA and 20-nt 32P-labeled DNA probe were incubated together for 2 h at 37
◦C (DNA probe = 2.5 nM, mRNA = 10 nM) and then analyzed by native PAGE. The fraction of probe bound was calculated by dividing the
background-subtracted signal of the mRNA:probe band by the background-subtracted total signal for the lane. In this example, only one of
the probes has binding greater than 10% (probe 411). The total lane signal for probe 431 is visibly lower than for the other probes due to
differences in T4 PNK 50-phosphorylation efficiency, which is influenced by both sequence and structure.14
Probe start position: 666 671 676 686 691 696 706 711 716 726 731 736
0.04 0.04 0.13 0.15 0.17 0.21 0.25 0.13 0.25 0.15 0.14 0.06Fraction probe bound:
mRNA: probe 
probe 
Figure S13: Example RNAhyb gel 2: a representative gel quantifying mRNA accessibility. Here, we tested additional probes in a
relatively accessible region of the mRNA. For each probe, the mRNA and 20-nt 32P-labeled DNA probe were incubated together for 2 h at
37 ◦C (DNA probe = 2.5 nM, mRNA = 10 nM) and then analyzed by native PAGE. The fraction of probe bound was calculated by dividing
the background-subtracted signal of the mRNA:probe band by the background-subtracted total signal for the lane.
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S6.3 Comparison of experimental hybridization yields (RNAhyb) and computational accessibility
predictions (NUPACK) for mRNA input Y (d2EGFP)
Figure S14 compares RNAhyb probe hybridization yield against three computational proxies for mRNA accessibility calculated
using NUPACK: mRNA subsequence free energy, mRNA subsequence average equilibrium probability unpaired, equilibrium
fraction probe bound.
Using mRNA subsequence free energy (Figure S14a), it is striking that the data fall reliably in the lower right triangle.
Subsequences predicted to be inaccessible computationally (say G < −3 kcal/mol) are indeed shown to be poor binders
experimentally. On the other hand, subsequences predicted to be accessible computationally (say−3  G  0 kcal/mol) need
to be tested experimentally in order to find the subset that are indeed good binders. To reduce overall experimental effort, these
data suggest the approach of first computationally screening the mRNA subsequences to identify those with −3  G  0
kcal/mol and then using the RNAhyb gel assay to experimentally identify accessible windows from within this reduced set
of subsequences; further study is warranted. In the context of the full-length mRNA, there will be base-pairing between
subsequences as well as within subsequences, so the present approach of examining the free energy of each subsequence
represents only a simple computational proxy for accessibility.
The other computational proxies do not provide useful information. Average equilibrium fraction unpaired (Figure S14b)
produces both high and low values for the good binders, and hence does not provide a basis for narrowing the field in the
search for good binders. Equilibrium fraction probe bound (Figure S14c) is predicted to be high for all probes, hence is not
useful in discriminating between good and bad binders; note that the RNAhyb experiments use DNA probes (to reduce cost)
and the NUPACK calculations use RNA probes (because NUPACK does not include parameters for DNA:RNA interactions),
which reduces the comparability of the experimental and computational hybridization yields. The NUPACK calculations also
do not take into account pseudoknots, tertiary structure effects, and kinetic effects, all of which may contribute to the measured
experimental binding properties.
-10 -8 -6 -4 -2 0
Computational mRNA subsequence 
free energy (kcal/mol)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Ex
pe
rim
en
ta
l fr
ac
tio
n 
of
 p
ro
be
 b
ou
nd
0 0.2 0.4 0.6 0.8 1
Computational mRNA subsequence 
average equilibrium unpaired probability
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Ex
pe
rim
en
ta
l fr
ac
tio
n 
of
 p
ro
be
 b
ou
nd
0 0.2 0.4 0.6 0.8 1
Computational equilibrium 
fraction of probe bound
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Ex
pe
rim
en
ta
l fr
ac
tio
n 
of
 p
ro
be
 b
ou
ndyield ≥ 0.1 
0.05 < yield ≤ 0.1 
yield ≤ 0.05 
a b c
Figure S14: Comparison of experimental hybridization yields (RNAhyb) and computational accessibility predictions (NUPACK) for
mRNA input Y (d2EGFP). (a) Experimental fraction probe bound (mean over replicates of Table S4 and Figure S11) vs computed mRNA
subsequence free energy ( G ⌘ −kBT logQ, where Q is the partition function over the ensemble of all unpseudoknotted secondary
structures for the 20-nt mRNA subsequence, kB is the Boltzmann constant, and T is temperature). G ⇡ 0 for a window predicted to have
negligible base-pairing, G becomes increasingly negative as the probability of equilibrium base-pairing increases. Calculations performed
for one 20-nt mRNA subsequence at a time in 1M Na+ at 37 ◦C.4 (b) Experimental fraction probe bound vs computed mRNA subsequence
average equilibrium unpaired probability (the equilibrium probability of being unpaired averaged over each 20-nt subsequence). Calculation
performed for full mRNA in 1M Na+ at 37 ◦C4 followed by averaging over 20 nt for each subsequence. (c) Experimental fraction probe
bound vs computed equilibrium fraction probe bound. Note that the experiments use DNA probes (to reduce cost) and the calculations use
RNA probes (because NUPACK does not include parameters for DNA:RNA interactions). Calculations performed for one RNA probe at a
time (2.5 nM) together with full mRNA (10 nM) in 1M Na+ at 37 ◦C.4
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S7 Chemical modification studies
Initially, we performed all scRNA studies using 20OMe-RNA for strand A (to prevent Dicer processing of scRNA A·B) and
unmodified RNA for strand B (to permit Dicer processing of shRNA B). However, for the reverse mechanism (Y a X), strand B
was rapidly degraded when scRNAA·Bwas introduced into lysate (Figure S15, modificationM0); interestingly, the same strand
was considerably more resistant to degradation when in shRNA form. Modifying B is challenging because the modifications
must protect B from degradation in the lysate (including in the A·B scRNA complex), but still allow Dicer to cleave shRNA B
into siRNAs. Thus, the strategy of using 20OMe-RNA for B, which was our solution for protecting A from degradation, was
not feasible since it interferes with Dicer cleavage (Figure S15, modification M1). We tested a number of modifications for the
reverse mechanism (Figure S15 and Table S6) before discovering that using 1 nt of 20OMe-RNA at each end of B was sufficient
to provide good protection against degradation while permitting efficient Dicer processing. The same 1-nt end modifications
also proved to work well for the forward mechanism (Figure S16).
S7.1 Sequence composition of tested chemical modifications
a Forward mechanism (X a Y)
Modification Strand Sequence
M0 B 50-UUCAAGAUCCGCCACAACAGAUGCCAAAUAAAGCAAUAGCAUCUGUUGUGGC32PGGAUCUUGAAGU-30
M0 B1 50-UUCAAGAUCCGCCACAACAGAUGCCAAAUAAAGCAAUAGCAUCUGUUGUGGC-30
M0 B2 50-GGAUCUUGAAGU-30
M6 B 50-UUCAAGAUCCGCCACAACAGAUGCCAAAUAAAGCAAUAGCAUCUGUUGUGGC32PGGAUCUUGAAGU-30
M6 B1 50-UUCAAGAUCCGCCACAACAGAUGCCAAAUAAAGCAAUAGCAUCUGUUGUGGC-30
M6 B2 50-GGAUCUUGAAGU-30
b Reverse mechanism (Y a X)
Modification Strand Sequence
M0 B 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGCU-30
M0 B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
M0 B2 50-GAAAUUUGUGAUGCU-30
M1 B 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGCU-30
M1 B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
M1 B2 50-GAAAUUUGUGAUGCU-30
M2 B 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGCU-30
M2 B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
M2 B2 50-GAAAUUUGUGAUGCU-30
M3 B 50-C#A#U#CACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAU#G#C#U-30
M3 B1 50-C#A#U#CACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
M3 B2 50-GAAAUUUGUGAU#G#C#U-30
M4 B 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGCU-30
M4 B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
M4 B2 50-GAAAUUUGUGAUGCU-30 (same as M0 B2)
M5 B 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGdTdT-30
M5 B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30 (same as M0 B1)
M5 B2 50-GAAAUUUGUGAUGdTdT-30
M6 B 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU32PGAAAUUUGUGAUGCU-30
M6 B1 50-CAUCACAAAUUUCACAAAUACUCCCACAUGGUCCUGCUGGAGUAUUUGU-30
M6 B2 50-GAAAUUUGUGAUGCU-30
Table S5: Chemical modifications tested for shRNA B. (a) Forward mechanism (X a Y). (b) Reverse mechanism (Y a X). Sequences
constrained by mRNA X (DsRed2) are shown in magenta; sequences constrained by mRNA Y (d2EGFP) are shown in green. 20OMe-RNA
nucleotides are underlined. DNA nucleotides are indicated by the prefix ‘d’. Phosphorothioate backbone modifications are indicated with an
#. All other nucleotides are unmodified RNA. B oligonucleotides were constructed via ligation of B1 and 50-32P labeled B2 to incorporate
32P into the backbone of B at the depicted location.
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S7.2 RNase degradation and Dicer processing studies
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Figure S15: RNase degradation and Dicer processing of chemically modified shRNAB for the reverse mechanism (Y aX). Comparison
of unmodified B (denoted M0) to six different chemical modifications (M1, . . . , M6). Modifications to B must protect A·B from RNase
degradation in lysate but still allow Dicer to cleave shRNA B into siRNAs. Experimental conditions: 2.5 nM A·B (A is 100% 20OMe-RNA)
or B were incubated in 1⇥ Buffer D or 1.25 µg/µL wildtype lysate for 2 h at 37 ◦C and then separated by native PAGE. Gels from multiple
experiments are displayed together for illustrative purposes (separated by vertical lines). Modifications M2 and M6 were the most successful,
indicating that preventing nuclease activity at the 50 and 30 ends through 20OMe-RNA modifications is a good strategy.
scRNA A·B in lysate shRNA B
Modification Description relative to buffer cleaved to siRNAs
M0 RNA (unmodified) 9% 81%
M1 20OMe-RNA except 4 nt RNA at ligation site 233% 1%
M2 3 nt 20OMe-RNA at 50 and 30 ends 118% 60%
M3 3 nt phosphorothioate backbone at 50 and 30 ends 94% 18%
M4 20OMe-RNA loop (14 nt) plus alternating 20OMe-RNA 33% 37%
for siRNA sense strand (9 nt)
M5 2 nt DNA at 30 end – 6%
M6 1 nt 20OMe-RNA at 50 and 30 ends 97% 83%
Table S6: RNase degradation and Dicer processing of chemically modified shRNA B for the reverse mechanism (Y a X). Protection
from degradation is calculated as the percent A·B signal in lysate relative to buffer (background-subtracted A·B signal in lysate normalized by
the background subtracted A·B signal in buffer). Complete protection from degradation would correspond to 100%. There is some variation
due to well loading, but it is unclear whyM1 A·B has significantly more signal in the lysate lane compared to the buffer lane. Dicer processing
is calculated as the percent B processed into siRNAs in lysate (background-subtracted siRNA band normalized by the background-subtracted
signal for the full lane). Complete Dicer processing of shRNA B would correspond to 100%. Modification M6 was determined to be the best
modification to shRNA B due to the near complete protection of A·B from degradation while allowing >80% cleavage of shRNA B.
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Figure S16: RNase degradation and Dicer processing of chemically modified shRNA B for the forward mechanism (X a Y). Modifi-
cation M6 provides protection from degradation (lane 6) without impeding Dicer processing into siRNAs (lane 8). Experimental conditions:
2.5 nM A·B (A is 100% 20OMe-RNA) or B were incubated in 1⇥ Buffer D or 1.25 µg/µL wildtype lysate for 2 h at 37 ◦C and then separated
by native PAGE. Gels from multiple experiments are displayed together for illustrative purposes (separated by vertical lines).
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